Chest, Vol 100, 703-708, Copyright © 1991 by American College of Chest Physicians

ARTICLES

Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes

ML Brantly, JT Wittes, CF Vogelmeier, RC Hubbard, GA Fells and RG Crystal
Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.

Diagnosis of the hereditary disorder alpha 1-antitrypsin (alpha 1AT) deficiency is critically dependent on quantification of serum levels of alpha 1AT, a 52-kDa antiprotease that serves to protect the lung from destruction by neutrophil elastase. Although the measurement of serum alpha 1AT levels is not difficult, there is no international standard for alpha 1AT, and investigators in the field recognize that widely used commercially available standards vary by as much as 50 percent. To establish accurate ranges for the common normal and deficient alpha 1AT phenotypes, the present study uses a purified alpha 1AT standard to quantify the alpha 1AT serum levels of 443 individuals with common normal and deficient alpha 1AT phenotypes, including MM, ZZ, SS, MZ, MS, and SZ. Based on the observed values, a statistical model was developed to generate predicted frequency distributions of alpha 1AT serum levels for each of these phenotypes. Based on these studies, the ranges (5th to 95th percentile) for alpha 1AT serum levels of the common phenotypes are: MM, 20 to 53 mumol/L; SS, 20 to 48 mumol/L; ZZ, 3.4 to 7.0 mumol/L; MZ, 15 to 42 mumol/L; MS, 18 to 52 mumol/L; and SZ, 10 to 23 mumol/L. This alpha 1AT standard and these ranges are being used for the National alpha 1-Antitrypsin Deficiency Registry organized under the auspices of the National Heart, Lung, and Blood Institute.

This article has been cited by other articles:

				O. Senn, E. W. Russi, M. Imboden, and N. M. Probst-Hensch {alpha}1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants Eur. Respir. J., November 1, 2005; 26(5): 909 - 917. [Abstract] [Full Text] [PDF]

				M. Dahl, C. P. Hersh, N. P. Ly, C. S. Berkey, E. K. Silverman, and B. G. Nordestgaard The protease inhibitor PI*S allele and COPD: a meta-analysis Eur. Respir. J., July 1, 2005; 26(1): 67 - 76. [Abstract] [Full Text] [PDF]

				M. E. J. Wadsworth, L. E. Vinall, A. L. Jones, R. J. Hardy, D. B. Whitehouse, S. L. Butterworth, W. S. Hilder, J. U. Lovegrove, and D. M. Swallow Alpha1-Antitrypsin as a Risk for Infant and Adult Respiratory Outcomes in a National Birth Cohort Am. J. Respir. Cell Mol. Biol., November 1, 2004; 31(5): 559 - 564. [Abstract] [Full Text] [PDF]

				L. T. Spencer, G. Paone, P. M. Krein, F. N. Rouhani, J. Rivera-Nieves, and M. L. Brantly Role of human neutrophil peptides in lung inflammation associated with {alpha}1-antitrypsin deficiency Am J Physiol Lung Cell Mol Physiol, March 1, 2004; 286(3): L514 - L520. [Abstract] [Full Text] [PDF]

				American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 818 - 900. [Full Text] [PDF]

				M. Dahl, A. Tybjaerg-Hansen, H. Sillesen, G. Jensen, R. Steffensen, and B. G. Nordestgaard Blood Pressure, Risk of Ischemic Cerebrovascular and Ischemic Heart Disease, and Longevity in {alpha}1-Antitrypsin Deficiency: The Copenhagen City Heart Study Circulation, February 11, 2003; 107(5): 747 - 752. [Abstract] [Full Text] [PDF]

				Y. Takubo, A. Guerassimov, H. Ghezzo, A. Triantafillopoulos, J. H. T. Bates, J. R. Hoidal, and M. G. Cosio {alpha}1-Antitrypsin Determines the Pattern of Emphysema and Function in Tobacco Smoke-exposed Mice: Parallels with Human Disease Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1596 - 1603. [Abstract] [Full Text] [PDF]

				J. K. Stoller, F. Rouhani, M. Brantly, S. Shahin, R. A. Dweik, J. M. Stocks, J. Clausen, E. Campbell, and F. Norton Biochemical Efficacy and Safety of a New Pooled Human Plasma {alpha}1-Antitrypsin, Respitin* Chest, July 1, 2002; 122(1): 66 - 74. [Abstract] [Full Text] [PDF]

				M. Dahl, A. Tybjaerg-Hansen, P. Lange, J. Vestbo, and B. G. Nordestgaard Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in {alpha}1-Antitrypsin MZ Heterozygotes: A Longitudinal Study of the General Population Ann Intern Med, February 19, 2002; 136(4): 270 - 279. [Abstract] [Full Text] [PDF]

				C. L. Bristow, H. Patel, and R. R. Arnold Self Antigen Prognostic for Human Immunodeficiency Virus Disease Progression Clin. Vaccine Immunol., September 1, 2001; 8(5): 937 - 942. [Abstract] [Full Text] [PDF]

				M. Dahl, B. G. Nordestgaard, P. Lange, J. Vestbo, and A. Tybjarg-Hansen Molecular Diagnosis of Intermediate and Severe {{alpha}}1-Antitrypsin Deficiency: MZ Individuals with Chronic Obstructive Pulmonary Disease May Have Lower Lung Function Than MM Individuals Clin. Chem., January 1, 2001; 47(1): 56 - 62. [Abstract] [Full Text] [PDF]

				A. J. SANDFORD, T. CHAGANI, J. J. SPINELLI, and P. D. PARE alpha 1-Antitrypsin Genotypes and the Acute-phase Response to Open Heart Surgery Am. J. Respir. Crit. Care Med., May 1, 1999; 159(5): 1624 - 1628. [Abstract] [Full Text] [PDF]

				S. Song, M. Morgan, T. Ellis, A. Poirier, K. Chesnut, J. Wang, M. Brantly, N. Muzyczka, B. J. Byrne, M. Atkinson, et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors PNAS, November 24, 1998; 95(24): 14384 - 14388. [Abstract] [Full Text] [PDF]

				C. Taggart, D. Cervantes-Laurean, G. Kim, N. G. McElvaney, N. Wehr, J. Moss, and R. L. Levine Oxidation of either Methionine 351 or Methionine 358 in alpha 1-Antitrypsin Causes Loss of Anti-neutrophil Elastase Activity J. Biol. Chem., August 25, 2000; 275(35): 27258 - 27265. [Abstract] [Full Text] [PDF]